NASDAQ:HOOK Hookipa Pharma (HOOK) Stock Price, News & Analysis $4.05 -0.05 (-1.22%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Hookipa Pharma Stock (NASDAQ:HOOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hookipa Pharma alerts:Sign Up Key Stats Today's Range$4.00▼$4.2850-Day Range$4.05▼$5.8252-Week Range$3.91▼$11.30Volume24,335 shsAverage Volume58,927 shsMarket Capitalization$40.07 millionP/E RatioN/ADividend YieldN/APrice Target$44.67Consensus RatingBuy Company OverviewHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Read More… How a $200,000 Mistake Unlocked a $118 Billion Gold Treasure (Ad)The window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Click here now to learn how you can position yourself for potentially massive gains. Hookipa Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks42nd Percentile Overall ScoreHOOK MarketRank™: Hookipa Pharma scored higher than 42% of companies evaluated by MarketBeat, and ranked 703rd out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHookipa Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHookipa Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Hookipa Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Hookipa Pharma are expected to decrease in the coming year, from ($3.80) to ($7.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hookipa Pharma is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hookipa Pharma is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHookipa Pharma has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Hookipa Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.66% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently increased by 112.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHookipa Pharma does not currently pay a dividend.Dividend GrowthHookipa Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.66% of the float of Hookipa Pharma has been sold short.Short Interest Ratio / Days to CoverHookipa Pharma has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hookipa Pharma has recently increased by 112.81%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for HOOK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hookipa Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Hookipa Pharma is held by insiders.Percentage Held by Institutions63.88% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hookipa Pharma's insider trading history. Receive HOOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HOOK Stock News HeadlinesShort Interest in Hookipa Pharma Inc (NASDAQ:HOOK) Rises By 112.8%September 26, 2024 | americanbankingnews.comHOOKIPA Pharma to Present Strong Preclinical HB-700 DatasetSeptember 24, 2024 | globenewswire.comNext opportunity for crypto millionsAs October unfolds and the effects of the Fed Pivot ripple through the market, this crypto could skyrocket. Want to know more?October 6, 2024 | Crypto 101 Media (Ad)HOOKIPA Pharma (NASDAQ:HOOK) Stock Quotes, Forecast and News SummarySeptember 11, 2024 | benzinga.comHOOKIPA Pharma Announces Board of Directors ChangesAugust 30, 2024 | globenewswire.comHOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comHOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss ExpectationsAugust 11, 2024 | finance.yahoo.comBuy Rating and Price Target Increase for Hookipa Pharma Amid Clinical and Financial ProgressAugust 10, 2024 | markets.businessinsider.comSee More Headlines HOOK Stock Analysis - Frequently Asked Questions How have HOOK shares performed this year? Hookipa Pharma's stock was trading at $8.10 on January 1st, 2024. Since then, HOOK stock has decreased by 50.0% and is now trading at $4.05. View the best growth stocks for 2024 here. How were Hookipa Pharma's earnings last quarter? Hookipa Pharma Inc (NASDAQ:HOOK) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.08. The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $5.68 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 36.81% and a negative net margin of 93.16%. When did Hookipa Pharma's stock split? Hookipa Pharma shares reverse split on Wednesday, July 10th 2024. The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Hookipa Pharma IPO? Hookipa Pharma (HOOK) raised $100 million in an initial public offering (IPO) on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager. How do I buy shares of Hookipa Pharma? Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Hookipa Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hookipa Pharma investors own include Homology Medicines (FIXX), Kaleido Biosciences (KLDO), Editas Medicine (EDIT), Gossamer Bio (GOSS), Atreca (BCEL), LogicBio Therapeutics (LOGC) and Alector (ALEC). Company Calendar Last Earnings8/08/2024Today10/05/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HOOK CUSIPN/A CIK1760542 Webwww.hookipapharma.com Phone431-890-6360Fax43-1890-636-0399Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$44.67 High Stock Price Target$60.00 Low Stock Price Target$24.00 Potential Upside/Downside+1,002.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net Margins-93.16% Pretax Margin-92.85% Return on Equity-36.81% Return on Assets-23.18% Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual Sales$52.16 million Price / Sales0.77 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book0.45Miscellaneous Outstanding Shares9,895,000Free Float9,568,000Market Cap$40.07 million OptionableOptionable Beta0.84 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:HOOK) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersThe panic button has already been pressedIf you missed it, my emergency election broadcast is now available on replay.Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.